Qubit Pharmaceuticals is a Paris and Boston-based quantum-enhanced drug discovery company founded in 2020 that accelerates pharmaceutical research using hybrid quantum-classical computing through their Atlas platform, achieving molecular simulations 100,000 times faster than traditional methods while reducing drug candidate screening from 5,000 to 200 compounds, with breakthrough technologies including the Hyperion-1 quantum emulator simulating 40 qubits and the FeNNix-Bio1 quantum AI foundation model developed with Sorbonne University, operating one of France’s largest GPU supercomputers and advancing 7 therapeutic programs particularly in oncology and inflammation.
Robert Marino (Co-founder, CEO), Louis-Paul Henry (Co-founder, CTO)
Explore other quantum computing companies in similar categories or regions.
Private
$45M
2 funding rounds tracked. View detailed investment history →
Information for Educational Purposes Only: All information about Qubit Pharmaceuticals is provided for informational and educational purposes only. This is not investment, financial, or professional advice.
No Warranties: While we strive for accuracy, Quantum Zeitgeist makes no warranties regarding the accuracy, completeness, or timeliness of company information. The quantum technology industry evolves rapidly, and information may become outdated.
No Endorsement: Inclusion in Quantum Navigator does not constitute an endorsement, recommendation, or verification of Qubit Pharmaceuticals's claims, technology, or business viability.
Do Your Own Research: Always conduct independent due diligence and consult qualified professionals (financial advisors, lawyers, etc.) before making investment, business, or career decisions.
For more information, see our Terms of Service and Privacy Policy.